Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Protalix BioTherapeutics Inc’s stock clocked out at $1.64, up 1.86% from its previous closing price of $1.61. In other words, the price has increased by $1.86 from its previous closing price. On the day, 0.54 million shares were traded. PLX stock price reached its highest trading level at $1.655 during the session, while it also had its lowest trading level at $1.605.
Ratios:
To gain a deeper understanding of PLX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.69 and its Current Ratio is at 2.49. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 08, 2020, Reiterated its Buy rating but revised its target price to $11 from $3 previously.
On April 17, 2017, Rodman & Renshaw reiterated its Buy rating and also lowered its target price recommendation from $4 to $5.
On April 04, 2016, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $3.50.Rodman & Renshaw initiated its Buy rating on April 04, 2016, with a $3.50 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 10 ’25 when Schwartz Aharon bought 129,000 shares for $1.60 per share. The transaction valued at 205,884 led to the insider holds 303,000 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PLX now has a Market Capitalization of 130555648 and an Enterprise Value of 101048672. As of this moment, Protalix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 39.05, and their Forward P/E ratio for the next fiscal year is 3.64. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.18 while its Price-to-Book (P/B) ratio in mrq is 2.83. Its current Enterprise Value per Revenue stands at 1.691 whereas that against EBITDA is 16.966.
Stock Price History:
The Beta on a monthly basis for PLX is -0.24, which has changed by 0.76344085 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, PLX has reached a high of $3.10, while it has fallen to a 52-week low of $0.82. The 50-Day Moving Average of the stock is 9.55%, while the 200-Day Moving Average is calculated to be -15.61%.
Shares Statistics:
It appears that PLX traded 944.05K shares on average per day over the past three months and 456580 shares per day over the past ten days. A total of 78.13M shares are outstanding, with a floating share count of 76.20M. Insiders hold about 4.28% of the company’s shares, while institutions hold 12.74% stake in the company. Shares short for PLX as of 1753920000 were 3631108 with a Short Ratio of 3.85, compared to 1751241600 on 3270635. Therefore, it implies a Short% of Shares Outstanding of 3631108 and a Short% of Float of 4.760000000000001.
Revenue Estimates
In the current quarter, 2 analysts expect revenue to total $13.49M. It ranges from a high estimate of $15.41M to a low estimate of $11.56M. As of the current estimate, Protalix BioTherapeutics Inc’s year-ago sales were $13.3MFor the next quarter, 2 analysts are estimating revenue of $17.72M. There is a high estimate of $18.17M for the next quarter, whereas the lowest estimate is $17.28M.
A total of 2 analysts have provided revenue estimates for PLX’s current fiscal year. The highest revenue estimate was $60.71M, while the lowest revenue estimate was $55.1M, resulting in an average revenue estimate of $57.91M. In the same quarter a year ago, actual revenue was $53.4MBased on 2 analysts’ estimates, the company’s revenue will be $106.2M in the next fiscal year. The high estimate is $119.46M and the low estimate is $92.94M.
